Endo plunks down $637M for Indevus

Endo Pharmaceuticals says it will be acquiring Indevus Pharmaceuticals for $370 million in cash and an additional $267 in future payouts, in an effort to move away from the pain-management business and into more-lucrative therapeutic areas with a less competition. Release

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.